利索凝胶治疗R/R滤泡性淋巴瘤患者取得良好疗效

IF 81.1 1区 医学 Q1 ONCOLOGY
Diana Romero
{"title":"利索凝胶治疗R/R滤泡性淋巴瘤患者取得良好疗效","authors":"Diana Romero","doi":"10.1038/s41571-024-00920-z","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"21 9","pages":"639-639"},"PeriodicalIF":81.1000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Promising outcomes with liso-cel in patients with R/R follicular lymphoma\",\"authors\":\"Diana Romero\",\"doi\":\"10.1038/s41571-024-00920-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"21 9\",\"pages\":\"639-639\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2024-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41571-024-00920-z\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41571-024-00920-z","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

滤泡性淋巴瘤(FL)患者在接受一线免疫化疗后一般都能获得良好的疗效;然而,对于复发和/或难治性(R/R)疾病患者,尤其是患有高危疾病的患者,治疗方案却很有限。现在,TRANSCEND FL 二期试验的数据证明了 CD19 靶向嵌合抗原受体(CAR)T 细胞产品 lisocabtagene maraleucel(liso-cel)对复发性/难治性 FL 患者的疗效。在2L治疗中,96%的患者获得了客观应答,全部为CR。12个月时,接受3L+和2L liso-cel治疗的患者的反应持续率分别为82%和90%;无进展生存率分别为81%和91%;总生存率分别为92%和96%。在中位随访时间至少为16.6个月时,两组患者均未达到这些终点的中位持续时间。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Promising outcomes with liso-cel in patients with R/R follicular lymphoma

Promising outcomes with liso-cel in patients with R/R follicular lymphoma
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
99.40
自引率
0.40%
发文量
114
审稿时长
6-12 weeks
期刊介绍: Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信